Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Abbott Announces New Category of Biowearables at CES 2022

Here is a brief preview of this blast: During Abbott’s Keynote at CES 2022, Abbott announced plans to develop a new category of consumer Biowearables called “Lingo” designed to help people “understand their body’s unique language” (view Keynote Speech here starting at 1:22:22). These new sensors will separately monitor glucose, ketones, lactate, and alcohol biomarkers to allow patients to make better decisions about general health, nutrition, and athletic performance (view image below). Abbott did not disclose details on the launch timing; however, the company may provide additional context during its upcoming JPM Healthcare Conference presentation on Tuesday, January 11, 2022 at 9:00 AM ET. Below, FENIX provides insights on Abbott’s Lingo platform, including thoughts on how Dexcom’s G7 may be a catalyst for it to also expand into the wellness category.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.